APO Research
Talk to an analyst

APO RESEARCH · REPORT

Olaparib Tablets

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Olaparib Tablets Market Outlook and Growth Opportunities 2026

27 December 2025191 pages

Choose your research edition.

Industry ResearchOlaparib Tablets Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Olaparib Tablets Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Olaparib Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Olaparib Tablets Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Olaparib Tablets Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Olaparib Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Olaparib Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Olaparib Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Olaparib Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Olaparib Tablets market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Olaparib Tablets market include CSPC Ouyi Pharmaceutical, Qilu Pharmaceutical, Merck, Kelun Pharmaceutical, Sino Therapeutics, Jiangsu Litaier Pharmaceuticals, Huadong Medicin, Natco Pharma and Everest Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Olaparib Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Olaparib Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Olaparib Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Olaparib Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.

Olaparib Tablets Segment by Company

CSPC Ouyi Pharmaceutical

Qilu Pharmaceutical

Merck

Kelun Pharmaceutical

Sino Therapeutics

Jiangsu Litaier Pharmaceuticals

Huadong Medicin

Natco Pharma

Everest Pharmaceuticals

BDR Pharmaceuticals

AstraZeneca

Olaparib Tablets Segment by Type

100mg per Tablet

500mg per Tablet

Olaparib Tablets Segment by Application

Ovarian Cancer

Breast Cancer

Metastatic Prostate Cancer

Metastatic Pancreatic Cancer

Olaparib Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Olaparib Tablets status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Olaparib Tablets market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Olaparib Tablets significant trends, drivers, influence factors in global and regions.

6. To analyze Olaparib Tablets competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Olaparib Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Olaparib Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Olaparib Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Olaparib Tablets market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Olaparib Tablets industry.

Chapter 3: Detailed analysis of Olaparib Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Olaparib Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Olaparib Tablets in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Olaparib Tablets Industry Trends Table 2. Olaparib Tablets Industry Drivers Table 3. Olaparib Tablets Industry Opportunities and Challenges Table 4. Olaparib Tablets Industry Restraints Table 5. Global Olaparib Tablets Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Olaparib Tablets Revenue Share by Company (2021-2026) Table 7. Global Olaparib Tablets Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Olaparib Tablets Sales Volume Share by Company (2021-2026) Table 9. Global Olaparib Tablets Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Olaparib Tablets Company Ranking, (2024-2026) & (USD Million) Table 11. Global Olaparib Tablets Key Company Manufacturing Base & Headquarters Table 12. Global Olaparib Tablets Company, Product Type & Application Table 13. Global Olaparib Tablets Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Olaparib Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 100mg per Tablet Table 18. Significant Companies of 500mg per Tablet Table 19. Global Olaparib Tablets Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Olaparib Tablets Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Olaparib Tablets Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Olaparib Tablets Sales Volume Share by Type (2021-2026) Table 23. Global Olaparib Tablets Sales Volume Share by Type (2027-2032) Table 24. Global Olaparib Tablets Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Olaparib Tablets Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Olaparib Tablets Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Olaparib Tablets Sales Value Share by Type (2021-2026) Table 28. Global Olaparib Tablets Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Ovarian Cancer Table 30. Significant Companies of Breast Cancer Table 31. Significant Companies of Metastatic Prostate Cancer Table 32. Significant Companies of Metastatic Pancreatic Cancer Table 33. Global Olaparib Tablets Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Olaparib Tablets Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Olaparib Tablets Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Olaparib Tablets Sales Volume Share by Application (2021-2026) Table 37. Global Olaparib Tablets Sales Volume Share by Application (2027-2032) Table 38. Global Olaparib Tablets Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Olaparib Tablets Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Olaparib Tablets Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Olaparib Tablets Sales Value Share by Application (2021-2026) Table 42. Global Olaparib Tablets Sales Value Share by Application (2027-2032) Table 43. Global Olaparib Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Olaparib Tablets Sales by Region (2021-2026) & (K Units) Table 45. Global Olaparib Tablets Sales Market Share by Region (2021-2026) Table 46. Global Olaparib Tablets Sales by Region (2027-2032) & (K Units) Table 47. Global Olaparib Tablets Sales Market Share by Region (2027-2032) Table 48. Global Olaparib Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Olaparib Tablets Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Olaparib Tablets Sales Value Share by Region (2021-2026) Table 51. Global Olaparib Tablets Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Olaparib Tablets Sales Value Share by Region (2027-2032) Table 53. Global Olaparib Tablets Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Olaparib Tablets Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Olaparib Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Olaparib Tablets Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Olaparib Tablets Sales by Country (2021-2026) & (K Units) Table 58. Global Olaparib Tablets Sales Market Share by Country (2021-2026) Table 59. Global Olaparib Tablets Sales by Country (2027-2032) & (K Units) Table 60. Global Olaparib Tablets Sales Market Share by Country (2027-2032) Table 61. Global Olaparib Tablets Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Olaparib Tablets Sales Value Market Share by Country (2021-2026) Table 63. Global Olaparib Tablets Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Olaparib Tablets Sales Value Market Share by Country (2027-2032) Table 65. CSPC Ouyi Pharmaceutical Company Information Table 66. CSPC Ouyi Pharmaceutical Business Overview Table 67. CSPC Ouyi Pharmaceutical Olaparib Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. CSPC Ouyi Pharmaceutical Olaparib Tablets Product Portfolio Table 69. CSPC Ouyi Pharmaceutical Recent Development Table 70. Qilu Pharmaceutical Company Information Table 71. Qilu Pharmaceutical Business Overview Table 72. Qilu Pharmaceutical Olaparib Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Qilu Pharmaceutical Olaparib Tablets Product Portfolio Table 74. Qilu Pharmaceutical Recent Development Table 75. Merck Company Information Table 76. Merck Business Overview Table 77. Merck Olaparib Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Merck Olaparib Tablets Product Portfolio Table 79. Merck Recent Development Table 80. Kelun Pharmaceutical Company Information Table 81. Kelun Pharmaceutical Business Overview Table 82. Kelun Pharmaceutical Olaparib Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Kelun Pharmaceutical Olaparib Tablets Product Portfolio Table 84. Kelun Pharmaceutical Recent Development Table 85. Sino Therapeutics Company Information Table 86. Sino Therapeutics Business Overview Table 87. Sino Therapeutics Olaparib Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Sino Therapeutics Olaparib Tablets Product Portfolio Table 89. Sino Therapeutics Recent Development Table 90. Jiangsu Litaier Pharmaceuticals Company Information Table 91. Jiangsu Litaier Pharmaceuticals Business Overview Table 92. Jiangsu Litaier Pharmaceuticals Olaparib Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Jiangsu Litaier Pharmaceuticals Olaparib Tablets Product Portfolio Table 94. Jiangsu Litaier Pharmaceuticals Recent Development Table 95. Huadong Medicin Company Information Table 96. Huadong Medicin Business Overview Table 97. Huadong Medicin Olaparib Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Huadong Medicin Olaparib Tablets Product Portfolio Table 99. Huadong Medicin Recent Development Table 100. Natco Pharma Company Information Table 101. Natco Pharma Business Overview Table 102. Natco Pharma Olaparib Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Natco Pharma Olaparib Tablets Product Portfolio Table 104. Natco Pharma Recent Development Table 105. Everest Pharmaceuticals Company Information Table 106. Everest Pharmaceuticals Business Overview Table 107. Everest Pharmaceuticals Olaparib Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Everest Pharmaceuticals Olaparib Tablets Product Portfolio Table 109. Everest Pharmaceuticals Recent Development Table 110. BDR Pharmaceuticals Company Information Table 111. BDR Pharmaceuticals Business Overview Table 112. BDR Pharmaceuticals Olaparib Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. BDR Pharmaceuticals Olaparib Tablets Product Portfolio Table 114. BDR Pharmaceuticals Recent Development Table 115. AstraZeneca Company Information Table 116. AstraZeneca Business Overview Table 117. AstraZeneca Olaparib Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. AstraZeneca Olaparib Tablets Product Portfolio Table 119. AstraZeneca Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Olaparib Tablets Distributors List Table 123. Olaparib Tablets Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Olaparib Tablets Product Image Figure 2. Global Olaparib Tablets Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Olaparib Tablets Sales Value (2021-2032) & (US$ Million) Figure 4. Global Olaparib Tablets Sales (2021-2032) & (K Units) Figure 5. Global Olaparib Tablets Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Olaparib Tablets Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 100mg per Tablet Image Figure 10. 500mg per Tablet Image Figure 11. Global Olaparib Tablets Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Olaparib Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Olaparib Tablets Sales Volume Share by Type (2021-2032) Figure 14. Global Olaparib Tablets Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Olaparib Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Olaparib Tablets Sales Value Share by Type (2021-2032) Figure 17. Ovarian Cancer Image Figure 18. Breast Cancer Image Figure 19. Metastatic Prostate Cancer Image Figure 20. Metastatic Pancreatic Cancer Image Figure 21. Global Olaparib Tablets Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Olaparib Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Olaparib Tablets Sales Volume Share by Application (2021-2032) Figure 24. Global Olaparib Tablets Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Olaparib Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Olaparib Tablets Sales Value Share by Application (2021-2032) Figure 27. Global Olaparib Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Olaparib Tablets Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Olaparib Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Olaparib Tablets Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Olaparib Tablets Sales Value (2021-2032) & (US$ Million) Figure 32. North America Olaparib Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Olaparib Tablets Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Olaparib Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Olaparib Tablets Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Olaparib Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Olaparib Tablets Sales Value (2021-2032) & (US$ Million) Figure 38. South America Olaparib Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Olaparib Tablets Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Olaparib Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Olaparib Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Olaparib Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Olaparib Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Olaparib Tablets Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Olaparib Tablets Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg per Tablet
  • 500mg per Tablet
Applications
  • Ovarian Cancer
  • Breast Cancer
  • Metastatic Prostate Cancer
  • Metastatic Pancreatic Cancer
Companies covered
  • CSPC Ouyi Pharmaceutical
  • Qilu Pharmaceutical
  • Merck
  • Kelun Pharmaceutical
  • Sino Therapeutics
  • Jiangsu Litaier Pharmaceuticals
  • Huadong Medicin
  • Natco Pharma
  • Everest Pharmaceuticals
  • BDR Pharmaceuticals
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Olaparib Tablets Sales Value (2021-2032)
  4. 1.2.2 Global Olaparib Tablets Sales Volume (2021-2032)
  5. 1.2.3 Global Olaparib Tablets Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Olaparib Tablets Market Dynamics
  1. 2.1 Olaparib Tablets Industry Trends
  2. 2.2 Olaparib Tablets Industry Drivers
  3. 2.3 Olaparib Tablets Industry Opportunities and Challenges
  4. 2.4 Olaparib Tablets Industry Restraints
3 Olaparib Tablets Market by Company
  1. 3.1 Global Olaparib Tablets Company Revenue Ranking in 2025
  2. 3.2 Global Olaparib Tablets Revenue by Company (2021-2026)
  3. 3.3 Global Olaparib Tablets Sales Volume by Company (2021-2026)
  4. 3.4 Global Olaparib Tablets Average Price by Company (2021-2026)
  5. 3.5 Global Olaparib Tablets Company Ranking (2024-2026)
  6. 3.6 Global Olaparib Tablets Company Manufacturing Base and Headquarters
  7. 3.7 Global Olaparib Tablets Company Product Type and Application
  8. 3.8 Global Olaparib Tablets Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Olaparib Tablets Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Olaparib Tablets Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Olaparib Tablets Market by Type
  1. 4.1 Olaparib Tablets Type Introduction
  2. 4.1.1 100mg per Tablet
  3. 4.1.2 500mg per Tablet
  4. 4.2 Global Olaparib Tablets Sales Volume by Type
  5. 4.2.1 Global Olaparib Tablets Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Olaparib Tablets Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Olaparib Tablets Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Olaparib Tablets Sales Value by Type
  9. 4.3.1 Global Olaparib Tablets Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Olaparib Tablets Sales Value by Type (2021-2032)
  11. 4.3.3 Global Olaparib Tablets Sales Value Share by Type (2021-2032)
5 Olaparib Tablets Market by Application
  1. 5.1 Olaparib Tablets Application Introduction
  2. 5.1.1 Ovarian Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Metastatic Prostate Cancer
  5. 5.1.4 Metastatic Pancreatic Cancer
  6. 5.2 Global Olaparib Tablets Sales Volume by Application
  7. 5.2.1 Global Olaparib Tablets Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Olaparib Tablets Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Olaparib Tablets Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Olaparib Tablets Sales Value by Application
  11. 5.3.1 Global Olaparib Tablets Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Olaparib Tablets Sales Value by Application (2021-2032)
  13. 5.3.3 Global Olaparib Tablets Sales Value Share by Application (2021-2032)
6 Olaparib Tablets Regional Sales and Value Analysis
  1. 6.1 Global Olaparib Tablets Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Olaparib Tablets Sales by Region (2021-2032)
  3. 6.2.1 Global Olaparib Tablets Sales by Region: 2021-2026
  4. 6.2.2 Global Olaparib Tablets Sales by Region (2027-2032)
  5. 6.3 Global Olaparib Tablets Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Olaparib Tablets Sales Value by Region (2021-2032)
  7. 6.4.1 Global Olaparib Tablets Sales Value by Region: 2021-2026
  8. 6.4.2 Global Olaparib Tablets Sales Value by Region (2027-2032)
  9. 6.5 Global Olaparib Tablets Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Olaparib Tablets Sales Value (2021-2032)
  12. 6.6.2 North America Olaparib Tablets Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Olaparib Tablets Sales Value (2021-2032)
  15. 6.7.2 Europe Olaparib Tablets Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Olaparib Tablets Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Olaparib Tablets Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Olaparib Tablets Sales Value (2021-2032)
  21. 6.9.2 South America Olaparib Tablets Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Olaparib Tablets Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Olaparib Tablets Sales Value Share by Country, 2025 VS 2032
7 Olaparib Tablets Country-level Sales and Value Analysis
  1. 7.1 Global Olaparib Tablets Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Olaparib Tablets Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Olaparib Tablets Sales by Country (2021-2032)
  4. 7.3.1 Global Olaparib Tablets Sales by Country (2021-2026)
  5. 7.3.2 Global Olaparib Tablets Sales by Country (2027-2032)
  6. 7.4 Global Olaparib Tablets Sales Value by Country (2021-2032)
  7. 7.4.1 Global Olaparib Tablets Sales Value by Country (2021-2026)
  8. 7.4.2 Global Olaparib Tablets Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Olaparib Tablets Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Olaparib Tablets Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Olaparib Tablets Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Olaparib Tablets Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Olaparib Tablets Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Olaparib Tablets Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Olaparib Tablets Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Olaparib Tablets Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Olaparib Tablets Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Olaparib Tablets Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Olaparib Tablets Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Olaparib Tablets Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Olaparib Tablets Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Olaparib Tablets Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Olaparib Tablets Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Olaparib Tablets Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Olaparib Tablets Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Olaparib Tablets Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Olaparib Tablets Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Olaparib Tablets Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Olaparib Tablets Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Olaparib Tablets Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Olaparib Tablets Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Olaparib Tablets Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Olaparib Tablets Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Olaparib Tablets Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Olaparib Tablets Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Olaparib Tablets Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Olaparib Tablets Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Olaparib Tablets Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CSPC Ouyi Pharmaceutical
  2. 8.1.1 CSPC Ouyi Pharmaceutical Company Information
  3. 8.1.2 CSPC Ouyi Pharmaceutical Business Overview
  4. 8.1.3 CSPC Ouyi Pharmaceutical Olaparib Tablets Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CSPC Ouyi Pharmaceutical Olaparib Tablets Product Portfolio
  6. 8.1.5 CSPC Ouyi Pharmaceutical Recent Developments
  7. 8.2 Qilu Pharmaceutical
  8. 8.2.1 Qilu Pharmaceutical Company Information
  9. 8.2.2 Qilu Pharmaceutical Business Overview
  10. 8.2.3 Qilu Pharmaceutical Olaparib Tablets Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Qilu Pharmaceutical Olaparib Tablets Product Portfolio
  12. 8.2.5 Qilu Pharmaceutical Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Olaparib Tablets Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Olaparib Tablets Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Kelun Pharmaceutical
  20. 8.4.1 Kelun Pharmaceutical Company Information
  21. 8.4.2 Kelun Pharmaceutical Business Overview
  22. 8.4.3 Kelun Pharmaceutical Olaparib Tablets Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Kelun Pharmaceutical Olaparib Tablets Product Portfolio
  24. 8.4.5 Kelun Pharmaceutical Recent Developments
  25. 8.5 Sino Therapeutics
  26. 8.5.1 Sino Therapeutics Company Information
  27. 8.5.2 Sino Therapeutics Business Overview
  28. 8.5.3 Sino Therapeutics Olaparib Tablets Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sino Therapeutics Olaparib Tablets Product Portfolio
  30. 8.5.5 Sino Therapeutics Recent Developments
  31. 8.6 Jiangsu Litaier Pharmaceuticals
  32. 8.6.1 Jiangsu Litaier Pharmaceuticals Company Information
  33. 8.6.2 Jiangsu Litaier Pharmaceuticals Business Overview
  34. 8.6.3 Jiangsu Litaier Pharmaceuticals Olaparib Tablets Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Litaier Pharmaceuticals Olaparib Tablets Product Portfolio
  36. 8.6.5 Jiangsu Litaier Pharmaceuticals Recent Developments
  37. 8.7 Huadong Medicin
  38. 8.7.1 Huadong Medicin Company Information
  39. 8.7.2 Huadong Medicin Business Overview
  40. 8.7.3 Huadong Medicin Olaparib Tablets Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Huadong Medicin Olaparib Tablets Product Portfolio
  42. 8.7.5 Huadong Medicin Recent Developments
  43. 8.8 Natco Pharma
  44. 8.8.1 Natco Pharma Company Information
  45. 8.8.2 Natco Pharma Business Overview
  46. 8.8.3 Natco Pharma Olaparib Tablets Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Natco Pharma Olaparib Tablets Product Portfolio
  48. 8.8.5 Natco Pharma Recent Developments
  49. 8.9 Everest Pharmaceuticals
  50. 8.9.1 Everest Pharmaceuticals Company Information
  51. 8.9.2 Everest Pharmaceuticals Business Overview
  52. 8.9.3 Everest Pharmaceuticals Olaparib Tablets Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Everest Pharmaceuticals Olaparib Tablets Product Portfolio
  54. 8.9.5 Everest Pharmaceuticals Recent Developments
  55. 8.10 BDR Pharmaceuticals
  56. 8.10.1 BDR Pharmaceuticals Company Information
  57. 8.10.2 BDR Pharmaceuticals Business Overview
  58. 8.10.3 BDR Pharmaceuticals Olaparib Tablets Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 BDR Pharmaceuticals Olaparib Tablets Product Portfolio
  60. 8.10.5 BDR Pharmaceuticals Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Olaparib Tablets Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Olaparib Tablets Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Olaparib Tablets Value Chain Analysis
  2. 9.1.1 Olaparib Tablets Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Olaparib Tablets Sales Mode & Process
  6. 9.2 Olaparib Tablets Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Olaparib Tablets Distributors
  9. 9.2.3 Olaparib Tablets Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst